Information updates

Updated ASCIA Action Plans for Anaphylaxis and Allergic Reactions

Aug 10, 2016
ASCIA has released updated Action Plans for Anaphylaxis and Allergic Reactions on its website:

The main changes are an increased emphasis of key messages, inclusion of images to show how to position a person with anaphylaxis and revised wording regarding the importance of giving the adrenaline (epinephrine) autoinjector first, then asthma medication in a person with severe allergy and asthma.

All ASCIA anaphylaxis resources and e-training courses have been updated with the changes that have been made to the ASCIA action plans.

Instructions for the EpiPen® adrenaline autoinjector remain unchanged in Australia and New Zealand. However, ASCIA has added "Hold leg still" to the instructions.

If you have any questions regarding EpiPen® instructions please email the Alphapharm-Mylan Medical Affairs team on This email address is being protected from spambots. You need JavaScript enabled to view it. or phone 1800 274 276.

Patient outcomes can be improved by ensuring that acute management of anaphylaxis is consistent with ASCIA Action Plans. In an anaphylaxis emergency, ASCIA Action Plans provide guidance on how and when to give the adrenaline autoinjector.
It is therefore essential that all patients prescribed an adrenaline autoinjector are provided with an ASCIA Action Plan for Anaphylaxis.

ASCIA Action Plans should be reviewed when patients are reassessed by their doctor, and each time they obtain a new adrenaline autoinjector prescription, which is approximately every 12 to 18 months.

Content updated 10 August 2016

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.